TheTechno Optimist.

StoryFunding

BioAge prices an upsized $115M public stock offering

BioAge LabsBGE-102 (NLRP3)

BioAge priced an upsized public offering of 5,897,435 shares at $19.50, raising about $115M gross. Goldman Sachs, Piper Sandler and Citigroup managed the underwriting.

  • 5,897,435 shares at $19.50 per share; underwriters hold 30-day option for additional 884,615 shares.
  • Gross proceeds approximately $115M to fund BGE-102 and additional NLRP3 and APJ program development.
  • Joint book-running managers: Goldman Sachs, Piper Sandler and Citigroup; expected close January 23, 2026.
Read the original · Filing Longevity

More on BGE-102 (NLRP3)

Primer